The effect of TRIM on tumor outcomes has also been implemented in several cancerous diseases, including hepatocellular carcinoma [27], colorectal carcinoma [28], cervical carcinoma [29], esophageal carcinoma [30], and non-small cell lung cancers [31]. Here, TRAT1 is linked to hepatocellular carcinoma.